Correlation Between Eyenovia and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Eyenovia and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyenovia and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eyenovia and Molecular Partners AG, you can compare the effects of market volatilities on Eyenovia and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyenovia with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyenovia and Molecular Partners.

Diversification Opportunities for Eyenovia and Molecular Partners

-0.17

Correlation Coefficient

Eyenovia  Molecular Partners

Good diversification

The 3 months correlation between Eyenovia and Molecular is -0.17. Overlapping area represents the amount of risk that can be diversified away by holding Eyenovia and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Eyenovia is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyenovia are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Eyenovia i.e., Eyenovia and Molecular Partners go up and down completely randomly.

Pair Corralation between Eyenovia and Molecular Partners

Given the investment horizon of 90 days Eyenovia is expected to generate 8.3 times more return on investment than Molecular Partners. However, Eyenovia is 8.3 times more volatile than Molecular Partners AG. It trades about 0.32 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.05 per unit of risk. If you would invest  107.00  in Eyenovia on May 7, 2025 and sell it today you would earn a total of  1,329  from holding Eyenovia or generate 1242.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	67.21%
Values	Daily Returns

Eyenovia  vs.  Molecular Partners AG

Eyenovia

Risk-Adjusted Performance

Solid

Over the last 90 days Eyenovia has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very unsteady technical and fundamental indicators, Eyenovia displayed solid returns over the last few months and may actually be approaching a breakup point.

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Eyenovia and Molecular Partners

The main advantage of trading using opposite Eyenovia and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyenovia position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Eyenovia and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.